Bombesin Receptor Antagonists May Be Preferable to Agonists for Tumor Targeting
暂无分享,去创建一个
Anastasia Nikolopoulou | J. Reubi | B. Nock | T. Maina | A. Nikolopoulou | R. Cescato | Jean Claude Reubi | Renzo Cescato | Theodosia Maina | Berthold Nock | David Charalambidis | Véronique Piccand | V. Piccand | D. Charalambidis
[1] F Dumont,et al. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] Judit Erchegyi,et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.
[3] A. Sleight,et al. Radiolabelling of the human 5-HT2A receptor with an agonist, a partial agonist and an antagonist: effects on apparent agonist affinities. , 1996, Biochemical pharmacology.
[4] Hariprasad Gali,et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] O. Fackler,et al. The Nef protein of human immunodeficiency virus is a broad-spectrum modulator of chemokine receptor cell surface levels that acts independently of classical motifs for receptor endocytosis and Galphai signaling. , 2006, Molecular biology of the cell.
[6] J. Reubi,et al. Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[7] M. Impicciatore,et al. Action of bombesin on the motility of the stomach , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[8] Thangavel Arunachalam,et al. 177Lu-AMBA: Synthesis and characterization of a selective 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] T. Anekonda,et al. The Role of Anti-α-Enolase Autoantibodies in Pathogenicity of Autoimmune-Mediated Retinopathy , 2007, Journal of Clinical Immunology.
[10] J. Reubi,et al. Overexpression of Gastrin-Releasing Peptide Receptors in Tumor-Associated Blood Vessels of Human Ovarian Neoplasms , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.
[11] A. van der Eb,et al. A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.
[12] J. Reubi,et al. Synthesis and Evaluation of Bombesin Derivatives on the Basis of Pan-Bombesin Peptides Labeled with Indium-111, Lutetium-177, and Yttrium-90 for Targeting Bombesin Receptor-Expressing Tumors , 2004, Cancer Research.
[13] G. Vauquelin,et al. Slow antagonist dissociation and long-lasting in vivo receptor protection. , 2006, Trends in pharmacological sciences.
[14] J C Reubi,et al. Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast. , 1999, The American journal of pathology.
[15] A. Schally,et al. Hypothalamic Hormones and Cancer , 2001, Frontiers in Neuroendocrinology.
[16] S. Schulz,et al. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] W. Vale,et al. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors. , 1999, The Journal of pharmacology and experimental therapeutics.
[18] G. Loudos,et al. [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[19] G. Dockray,et al. Gut Peptides: Biochemistry and Physiology , 1994 .
[20] J. Reubi,et al. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study. , 2005, Journal of medicinal chemistry.
[21] J. Reubi,et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.
[22] G. Loudos,et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[23] J. Reubi,et al. Localization and characterization of neuropeptide receptors in human colon , 2001, Naunyn-Schmiedeberg's Archives of Pharmacology.
[24] J. Edwardson,et al. Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.
[25] J. Reubi. Peptide receptors as molecular targets for cancer diagnosis and therapy. , 2003, Endocrine reviews.
[26] A. Nunn,et al. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[27] R. Jensen,et al. Progress in the development of potent bombesin receptor antagonists. , 1991, Trends in pharmacological sciences.
[28] John D. Minna,et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.
[29] T. Anekonda,et al. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. , 2007, Journal of clinical immunology.
[30] V. Bennett,et al. Gastrin Releasing Peptide , 2008 .
[31] P. Mantyh,et al. Localization of specific binding sites for bombesin in the canine gastrointestinal tract. , 1987, Gastroenterology.
[32] T. Hoffman,et al. Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. , 2003, Nuclear medicine and biology.
[33] J C Reubi,et al. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. , 1999, Cancer research.
[34] J. Rivier,et al. Receptor Signaling and Endocytosis Are Differentially Regulated by Somatostatin Analogs , 2005, Molecular Pharmacology.
[35] A. Schally,et al. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers , 2000, Regulatory Peptides.
[36] G. Mariani,et al. Receptor radionuclide therapy of tumors: a road from basic research to clinical applications. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[37] R. Jensen,et al. Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity. , 1989, The Journal of biological chemistry.
[38] G. Slegers,et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study , 2000, European Journal of Nuclear Medicine.
[39] G. Vauquelin,et al. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO‐K1 cells expressing human angiotensin II AT1 receptors , 1999, British journal of pharmacology.
[40] J. Reubi,et al. Gastrin-releasing peptide receptors in normal and neoplastic human uterus: involvement of multiple tissue compartments. , 2005, The Journal of clinical endocrinology and metabolism.
[41] J. Reubi,et al. Bombesin Receptor Subtypes in Human Cancers: Detection with the Universal Radioligand 125I-[d-TYR6, β-ALA11, PHE13, NLE14] Bombesin(6–14) , 2002 .
[42] L. Mazzucchelli,et al. High expression of peptide receptors as a novel target in gastrointestinal stromal tumours , 2004, European Journal of Nuclear Medicine and Molecular Imaging.